PMV PHARMACEUTICALS INC (PMVP)

PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors

Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS...

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer

Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian...

PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights

Registrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt (PC14586), a first-in-class precision oncology investigational...

PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference

PRINCETON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and...

PMV to focus on lead drug, slashes workforce by 30% (NASDAQ:PMVP)

PMV Pharmaceuticals (PMVP) said it was cutting its workforce by around 30% as part of an effort to focus its resources on its lead drug candidate PC 14586. The

PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway

Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30%Unaudited cash, cash...

PMV Pharmaceuticals names Michael Carulli as CFO (NASDAQ:PMVP)

PMV Pharmaceuticals appoints Michael Carulli as CFO, succeeding Winston Kung. PC14586 clinical trial to begin in Q1 2024.

PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development

PC14586 clinical program to be led by Deepika Jalota, Pharm.D. (Chief Development Officer) and Marc Fellous, M.D. (Senior Vice President, Head of Clinical...

Commit To Buy PMV Pharmaceuticals At $2.50, Earn 24% Using Options

Ladenburg Thalmann starts PMV Pharmaceuticals at buy (NASDAQ:PMVP)

Ladenburg Thalmann has initiated coverage of PMV Pharmaceuticals (PMVP) with a buy rating, commenting that the stock is undervalued and oversold.

PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights

Updated data from Phase 1 PYNNACLE clinical trial of PC14586 presented at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer...

PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation

Updated PC14586 Phase 1 data presented today as a late-breaking poster at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer...

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar

PRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and...

PMVP Makes Bullish Cross Above Critical Moving Average

Commit To Buy PMV Pharmaceuticals At $5, Earn 141.9% Annualized Using Options

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Late-breaking poster presentation to highlight updated Phase 1 clinical data of PC14586, a first-in-class precision oncology investigational therapy, in...

Notable Tuesday Option Activity: TWLO, EOG, PMVP

Noteworthy Wednesday Option Activity: PMVP, SRPT, URI

PMV Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for PMVP

PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights

Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced...

PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference

PRINCETON, N.J., June 06, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and...

PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights

Continued progress in the ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with...

Relative Strength Alert For PMV Pharmaceuticals

PMV Pharmaceuticals Becomes Oversold (PMVP)

PMV Pharmaceuticals GAAP EPS of -$1.61 beats by $0.03 (NASDAQ:PMVP)

PMV Pharmaceuticals press release (PMVP): FY GAAP EPS of -$1.61 beats by $0.03.Cash, cash equivalents, and marketable securities of $243.5 million as of December 31, 2022

PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights

Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced...

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March

PRINCETON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the...